

References

I-166

1. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med*. 2015;373:621-31.
2. Weisel K. Spotlight on elotuzumab in the treatment of multiple myeloma: The evidence to date. *Onco Targets Ther*. 2016;6037-6048.
3. Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. *Lancet Haematol*. 2015;2(12):e516-e527.
4. Comeau J, Kelly K, Jean G. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. *Am J Health-Syst Pharm*. 2018;75:55-66.
5. Zhang T, Wang S, Lin T, et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. 2017;8(20): 34001-34017.
6. Dimopoulos M, Lonial S, Betts K, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. 2018;124(20):4032-4043.
7. Elotuzumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated date May 15, 2017.
8. Clinical Pharmacology™.Compendium. 2023. Tampa FL: Gold Standard, Inc. Elotuzumab.
9. Micromedex DrugDex Compendium®. 2023. Elotuzumab (Empliciti).
10. National Comprehensive Cancer Network (NCCN). Elotuzumab. NCCN Drugs and Biologics Compendium®. 2023.
11. Elotuzumab (Empliciti), for injection, for intravenous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised 3/2022.